Understand why a fragment, a full molecule and a commercial name cannot share evidence automatically.
The FDA describes the thymosin beta-4 fragment LKKTETQ as also known as TB-500. That distinction matters when a claim cites research about the full molecule. A fragment and a full molecule should not be treated as interchangeable merely because the names are related. Start by recording the precise research substance. If the source and the claim refer to different molecules, the connection needs evidence rather than an assumption based on familiar terminology.
For the fragment, the FDA reports that it has not identified human exposure data and that important safety information is lacking. That statement describes the agency’s information and assessment; it is not a declaration that every possible risk is known. Keep the limited wording intact. A lack of identified information cannot be rephrased as reassuring evidence, and an uncertainty statement should not become a definite prediction about an individual outcome.
Preparing the full guide…
The extended sections are available during your one-minute preview and with free email registration.
- Commercial names can hide a comparison problem
- A result belongs to its experimental setting
- Absence of data is not evidence of safety
- Do not combine unrelated evidence into one answer
- Build a short comparison table
- A careful conclusion keeps the distinction visible
Sources & further reading
Sources support specific statements, not every possible use of a molecule. Echo hub articles provide research background; original publications and official guidance are identified where supplied.
- FDA — Thymosin beta-4 fragment / TB-500
- Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment model (2015)
- The effect of thymosin treatment of venous ulcers (2010)